Donga Socio Holdings is a holding company that manages a diversified group of businesses across healthcare, logistics, and packaging. Its primary operating subsidiaries include Dong-A Pharmaceutical, which manufactures and sells over-the-counter medicines, health supplements, and consumer health products under the brand BAC; STGen Bio, a contract manufacturing organization specializing in biosimilars and biopharmaceuticals; Yongma Logistics, which provides third-party logistics and cold-chain services; and Dong-A Eco Pack, which produces glass bottles, plastic containers, and bottled water. The group serves domestic and international markets, with its logistics and packaging units supporting clients in the pharmaceutical, beverage, and food industries. Notable products include the BAC vitamin drink and the biosimilar Imudosa. The company was approved as a holding company in 2014.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Conglomerates Homepage donga.co.kr
Sector Industrials IR page donga.co.kr/investment/ir-2
Tags
holding company, over-the-counter medicines, biosimilars, contract manufacturing, third-party logistics, cold-chain logistics, glass packaging, plastic packaging, bottled water, health supplements, Dong-A Pharmaceutical, STGen Bio, Yongma Logistics, Dong-A Eco Pack, BAC, Imudosa, Dong-A Otsuka, Dong-A ST, Coupang, Pulmuone Sammul, Dongwon F&B, Coca-Cola, Woongjin Food
Press page —

Metrics

Valuation  
Market cap ₩ 636.823B
Market cap (USD) $ 468.691M
P/E 7.37
PEG 0.07
P/BV 0.53
P/S 0.42
P/OCF 2.57
P/FCF 3.32
Dividend yield —
Turnover / mcap —
Returns  
ROE 8.3%
ROI 8.0%
ROIC 8.6%
Profit margin 6.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 101.3%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 82.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.43T 1.333T 1.132T 1.015T 881.944B 783.316B 769.686B 707.496B 690.265B 726.166B 704.735B 630.625B 570.87B
Net profit 90.945B 58.022B 57.99B 11.153B 60.271B 162.345B 19.764B -163.977B 32.543B 149.051B 47.883B 1.716B 15.568B
Free cash flow 178.13B 33.43B 8.593B 19.351B 61.025B 32.644B 51.85B 33.197B 59.47B — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 113.56K — — — — — — — — — — — —
P/FCF 4.17 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 111B 82.6B 90.4B 91.6B 93.4B 102B 117B 113B 125B 144B
↳ YoY growth +33.0% -25.5% +9.5% +1.4% +2.0% +9.4% +14.9% -3.9% +10.7% +15.6%
↳ 5y CAGR +3.3% +1.4% +2.3% -1.6% +7.3% +4.5% +6.4% +9.1%
Borrowings, current (KRW) 332B 227B 220B 286B 214B 298B 383B 386B 471B 396B
Borrowings, non-current (KRW) 29.3B 171B 151B 120B 207B 186B 116B 202B 155B 162B
Lease liabilities (KRW) — — — 62.9B 66.8B 54.2B 52.6B 104B 114B 104B
Cash and deposits (KRW) 95.9B 179B 107B 86.8B 88.8B 99.6B 95.1B 120B 117B 123B
Intangible assets (KRW) 18.4B 26.5B 48.1B 45.7B 45.1B 113B 121B 132B 140B 105B
Right-of-use assets (KRW) — — — 62.1B 64.9B 52B 50.5B 101B 108B 96.7B
Net debt (borrowings + leases - cash) (KRW) -66.7B 219B 263B 382B 399B 438B 457B 572B 623B 540B
Cash flow detail
Operating cash flow (KRW) 30.5B 84.5B 58.3B 96.8B 84.6B 131B 75.9B 159B 83B 227B
Purchases of property, plant and equipment (KRW) -64.5B -25B -25.1B -44.9B -51.9B -70.1B -56.5B -150B -49.6B -49.3B
Purchases of intangible assets (KRW) -431M -4.41B -6.95B -218M -3.28B -8.67B -22.1B -9.41B -26B -9.35B
Dividends paid (cash effect) (KRW) -6.99B -6.05B -6.14B -6.14B -6.14B -9.18B -9.38B -12.5B -11.9B -10.8B
Share buybacks (cash effect) (KRW) — — — — -8.39B — — 0.00 0.00 -251M
Interest paid (cash effect) (KRW) -9.46B -9.77B -11.9B -9.85B -9.2B -7.46B -12.3B -22.7B -28.3B -26.3B
Income taxes paid (cash effect) (KRW) -19.9B -20.6B -6.35B -9.19B -10.6B -128M -21.2B -12.7B -28.4B 29.5B
Free cash flow (OCF - PPE - intangibles) (KRW) -34.5B 55.1B 26.2B 51.6B 29.4B 52.4B -2.72B -816M 7.44B 169B
Income detail
Research and development expense (KRW) — — — — — 6.52B 6.42B 7.39B — —
Total comprehensive income (KRW) 176B 33.1B -173B 19.8B 158B — 23B 40.6B 48.5B 98.6B
Comprehensive income to owners (KRW) 150B 33.1B -173B 19.6B 158B 63.2B 26.2B 43B 49B 98.1B
Reported Apr 2, 2018 Apr 2, 2018 Apr 1, 2019 Mar 30, 2020 Mar 19, 2021 Mar 20, 2024 Mar 21, 2025 Mar 18, 2026 Mar 18, 2026 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

주식등의대량보유상황보고서(일반) Bull 0 Bear 0 Routine

Prompts

Dong-A Pharmaceutical (ticker 000640), listed in South Korea.

Company History

Date Change Detail
Oct 16, 2026 Renamed Donga Socio Holdings → Dong-A Pharmaceutical

ETFs Holding Dong-A Pharmaceutical

ETF Weight in ETF Shares Market value As of
AVSE 0.01% 162 $ 10.822K Nov 16, 2026
AVEE 0.01% 203 $ 13.561K Nov 16, 2026
DFEV 0.01% 1,829 $ 127.024K Nov 12, 2026
DFSE 0.01% 462 $ 32.086K Nov 12, 2026
DEXC 0.00% 185 $ 12.848K Nov 12, 2026
DFEM 0.00% 4,469 $ 310.373K Nov 12, 2026
DFAE 0.00% 3,196 $ 221.963K Nov 12, 2026
DFAX 0.00% 2,578 $ 179.043K Nov 12, 2026
AVEM 0.00% 3,595 $ 240.158K Nov 16, 2026
AVXC 0.00% 121 $ 8,083.19 Nov 16, 2026